Form 4: Glaukos Director Denice Torres Receives Equity Compensation Awards

Glaukos Corp. Director Denice Torres has reported the acquisition of restricted stock units and stock options as part of her compensation, aligning her interests with shareholders.

Summary

• Denice Torres, a Director of Glaukos Corp. (GKOS), reported changes in her beneficial ownership of company securities via a Form 4 filing.
• On January 2, 2025, Ms. Torres acquired 461 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0, received in lieu of annual director retainer fees.
• These 461 RSUs are set to vest in full on the one-year anniversary of the grant date, January 2, 2026, and will be payable in an equivalent number of common shares.
• Following this transaction, Ms. Torres beneficially owned 19,603 shares, which included 3,072 unvested restricted stock units.
• On May 29, 2025, Ms. Torres acquired an additional 2,108 shares of Common Stock as restricted stock units at a price of $0, granted pursuant to the Issuer's Director Compensation Policy.
• These 2,108 RSUs are also set to vest in full on the one-year anniversary of the grant date, May 29, 2026, and will be payable in an equivalent number of common shares.
• Concurrently on May 29, 2025, Ms. Torres was granted 3,149 stock options with an exercise price of $94.87 per share.
• These stock options will vest in full on May 29, 2026, and have an expiration date of May 29, 2035.
• After the May 29, 2025 transactions, Ms. Torres's beneficial ownership increased to 21,711 shares of Common Stock, which includes 4,285 unvested restricted stock units, and she holds 3,149 stock options.

Sentiment

Score: 7

Explanation: The filing indicates standard equity compensation for a director, which is generally positive as it aligns insider interests with shareholders. It does not contain any negative or unexpected information.

Positives

• The grants of restricted stock units and stock options to a director align management's interests with those of shareholders, as the value of these awards is tied to the company's stock performance.
• The compensation structure, which includes equity awards, is a common practice in corporate governance to incentivize long-term value creation.

Risks

• The value of the equity compensation (RSUs and stock options) is subject to market fluctuations, meaning the actual realized value for the director could be lower than the grant date value if the stock price declines.
• Unvested restricted stock units represent a future obligation for the company to issue shares, which could lead to minor dilution upon vesting, though this is standard for equity compensation plans.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook. It solely reports insider equity transactions.

Industry Context

The granting of equity awards such as restricted stock units and stock options to directors is a standard practice across various industries, particularly in the medical technology and healthcare sectors where Glaukos operates. This compensation structure is designed to align the interests of directors with long-term shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as part of director compensation is a common and widely accepted practice among publicly traded companies, including those in the medical device and ophthalmology sectors.
• The vesting schedule of one year for RSUs and options is typical for annual grants to non-employee directors, aiming to retain talent and encourage sustained commitment.
• The exercise price of $94.87 for the stock options is likely the closing price of Glaukos stock on the grant date, which is standard practice to ensure compliance with tax and accounting rules.

Corporate Governance

Related Party Transactions

• The grants of restricted stock units and stock options to Denice Torres, a director of Glaukos Corp., constitute related party transactions as they involve compensation from the company to an insider. These transactions are part of the company's standard Director Compensation Policy.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with those of shareholders, potentially incentivizing decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this filing, as it pertains specifically to director compensation.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The restricted stock units granted on January 2, 2025, are expected to vest on January 2, 2026.
• The restricted stock units and stock options granted on May 29, 2025, are expected to vest on May 29, 2026.
• Upon vesting, the restricted stock units will be converted into an equivalent number of shares of Glaukos common stock.
• The director may choose to exercise the stock options at any time after vesting and before the expiration date of May 29, 2035.

Key Dates

Keywords

Glaukos, GKOS, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Beneficial Ownership, Equity Awards